B Douglas Smith

Acute myeloid leukemia is characterized by Wnt pathway inhibitor promoter hypermethylation

Michael A McDevitt, J. Herman, M. McDevitt, 2010, Leukemia & lymphoma.

Progressive chromatin repression and promoter methylation of CTNNA1 associated with advanced myeloid malignancies.

Wei Zhang, Jeanne Kowalski, Hua-Ling Tsai, 2009, Cancer research.

NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia.

Susan O'Brien, Jason Gotlib, Moshe Talpaz, 2009, Journal of the National Comprehensive Cancer Network : JNCCN.

The Case for Real-world Evidence in the Future of Clinical Research on Chronic Myeloid Leukemia.

B. Smith, B Douglas Smith, Jonathan Webster, 2019, Clinical therapeutics.

In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects.

B. Smith, M. Levis, D. Small, 2004, Blood.

MCL-1 as a Buffer for Proapoptotic BCL-2 Family Members during TRAIL-induced Apoptosis

David Loegering, Sun-Hee Lee, Chunrong Yu, 2007, Journal of Biological Chemistry.

Treatment options for chronic myeloid leukemia: imatinib versus interferon versus allogeneic transplant

Richard J. Jones, B. Smith, B Douglas Smith, 2004, Current opinion in oncology.

Economic burden associated with acute myeloid leukemia treatment

B. Skikne, B. Smith, A. Zeidan, 2016, Expert review of hematology.